<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31733721</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>08</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1548-5609</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>26</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Advances in chronic kidney disease</Title>
          <ISOAbbreviation>Adv Chronic Kidney Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lupus Podocytopathy: An Overview.</ArticleTitle>
        <Pagination>
          <StartPage>369</StartPage>
          <EndPage>375</EndPage>
          <MedlinePgn>369-375</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1053/j.ackd.2019.08.011</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1548-5595(19)30151-X</ELocationID>
        <Abstract>
          <AbstractText>In systemic lupus erythematosus, nephrotic-range proteinuria typically signals the presence of a proliferative lupus nephritis (class III/IV) and/or membranous lupus nephritis (class V, with or without concomitant class III or IV lesions). However, in rare instances, systemic lupus erythematosus patients with nephrotic syndrome have kidney biopsy findings of normal glomeruli or focal segmental glomerulosclerosis lesions, with or without mesangial proliferation, on light microscopy; the absence of subepithelial or subendothelial deposits on immunofluorescence and electron microscopy; and diffuse foot process effacement on electron microscopy. This pattern, termed lupus podocytopathy, is a unique form of lupus nephritis that mimics minimal change disease or primary focal segmental glomerulosclerosis and represents approximately 1% of lupus nephritis biopsies. Here we review the clinical features, histological manifestations, diagnostic criteria and classification, pathogenesis, treatment, and prognosis of lupus podocytopathy.</AbstractText>
          <CopyrightInformation>Copyright © 2019 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Oliva-Damaso</LastName>
            <ForeName>Nestor</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology, Department of Medicine, Hospital Costa del Sol, Marbella, Malaga, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Payan</LastName>
            <ForeName>Juan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology, Department of Medicine, Hospital Costa del Sol, Marbella, Malaga, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oliva-Damaso</LastName>
            <ForeName>Elena</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology, Department of Medicine, Hospital Doctor Negrin, Las Palmas de Gran Canaria, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pereda</LastName>
            <ForeName>Teresa</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Hospital Costa del Sol, Marbella, Malaga, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bomback</LastName>
            <ForeName>Andrew S</ForeName>
            <Initials>AS</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. Electronic address: asb68@cumc.columbia.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 MD009223</GrantID>
            <Acronym>MD</Acronym>
            <Agency>NIMHD NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Adv Chronic Kidney Dis</MedlineTA>
        <NlmUniqueID>101209214</NlmUniqueID>
        <ISSNLinking>1548-5595</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007678" MajorTopicYN="Y">Kidney Glomerulus</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009404" MajorTopicYN="N">Nephrotic Syndrome</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050199" MajorTopicYN="N">Podocytes</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Focal segmental glomerulosclerosis</Keyword>
        <Keyword MajorTopicYN="Y">Lupus nephritis</Keyword>
        <Keyword MajorTopicYN="Y">Lupus podocytopathy</Keyword>
        <Keyword MajorTopicYN="Y">Minimal change disease</Keyword>
        <Keyword MajorTopicYN="Y">Systemic lupus erythematosus</Keyword>
      </KeywordList>
      <CoiStatement>Financial Disclosure: The authors declare that they have no relevant financial interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31733721</ArticleId>
        <ArticleId IdType="mid">NIHMS1734188</ArticleId>
        <ArticleId IdType="pmc">PMC8405037</ArticleId>
        <ArticleId IdType="doi">10.1053/j.ackd.2019.08.011</ArticleId>
        <ArticleId IdType="pii">S1548-5595(19)30151-X</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16(1):175–179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15548564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu W, Chen Y, Wang S, et al.Clinical-morphological features and outcomes of lupus podocytopathy. Clin J Am Soc Nephrol. 2016;11(4):585–592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4822663</ArticleId>
            <ArticleId IdType="pubmed">26983707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dube GK, Markowitz GS, Radhakrishnan J, Appel GB, D’agati VD. Minimal change disease in systemic lupus erythematosus. Clin Nephrol. 2002;57(2):120–126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11863121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weening JJ, D’agati VD, Schwartz MM, et al.The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521–530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14717922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abuelo JG, Esparza AR, Garella S. Steroid-dependent nephrotic syndrome in lupus nephritis. Response to chlorambucil. Arch Intern Med. 1984;144(12):2411–2412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6508447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsumura N, Dohi K, Shiki H, et al.Three cases presenting with systemic lupus erythematosus and minimal change nephrotic syndrome (in Japanese). Jpn J Nephrol. 1989;31(9):991–999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2585838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okai T, Soejima A, Suzuki M, et al.A case report of lupus nephritis associated with minimal change nephrotic syndrome: comparison of various histological types of 67 cases with lupus nephritis (in Japanese). Jpn J Nephrol. 1992;34(7):835–840.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1479724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Makino H, Haramoto T, Shikata K, Ogura T, Ota Z. Minimal-change nephrotic syndrome associated with systemic lupus erythematosus. Am J Nephrol. 1995;15(5):439–441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7503146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hickman PL, Nolph KD, Jacobs R, Luger AM, Walker SE. Idiopathic focal segmental glomerulosclerosis in a patient with systemic lupus erythematosus: an unusual combination. Am J Kidney Dis. 1994;23(4):582–586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8154496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hertig A, Droz D, Lesavre P, Grünfeld JP, Rieu P. SLE and idiopathic nephrotic syndrome: coincidence or not? Am J Kidney Dis. 2002;40(6):1179–1184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12460036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bomback AS, Markowitz GS. Lupus podocytopathy: a distinct entity. Clin J Am Soc Nephrol. 2016;11(4):547–548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4822655</ArticleId>
            <ArticleId IdType="pubmed">26983708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen D, Hu W. Lupus podocytopathy: a distinct entity of lupus nephritis. J Nephrol. 2018;31(5):629–634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29270846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang YT, Chou HH, Chen FF, Chen MJ, Chiou YY. A case of minimal-change nephrotic syndrome in pediatric lupus erythematosus: just a coincidence? Lupus. 2006;15(4):244–247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16686266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bomback AS. Nonproliferative forms of lupus nephritis: an overview. Rheum Dis Clin North Am. 2018;44(4):561–569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8404975</ArticleId>
            <ArticleId IdType="pubmed">30274623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bomback AS. A pregnant woman with lupus and nephrotic-range proteinuria. Clin J Am Soc Nephrol. 2017;12(9):1534–1537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5586587</ArticleId>
            <ArticleId IdType="pubmed">28377471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salvatore SP, Barisoni LM, Herzenberg AM, Chander PN, Nickeleit V, Seshan SV. Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupus-like disease. Clin J Am Soc Nephrol. 2012;7(6):914–925.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22461531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haas M. Collapsing glomerulopathy in systemic lupus erythematosus: an extreme form of lupus podocytopathy? Clin J Am Soc Nephrol. 2012;7(6):878–880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22554717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang SF, Chen YH, Chen DQ, et al.Mesangial proliferative lupus nephritis with podocytopathy: a special entity of lupus nephritis. Lupus. 2018;27(2):303–311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28720048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han TS, Schwartz MM, Lewis EJ. Association of glomerular podocytopathy and nephrotic proteinuria in mesangial lupus nephritis. Lupus. 2006;15(2):71–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16539276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011;365(25):2398–2411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22187987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825–835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5477208</ArticleId>
            <ArticleId IdType="pubmed">27821390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F, Haas M, Glassock R, Zhao MH. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13(8):483–495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28669995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trivedi S, Zeier M, Reiser J. Role of podocytes in lupus nephritis. Nephrol Dial Transplant. 2009;24(12):3607–3612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19729466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cunard R, Kelly CJ. T cells and minimal change disease. J Am Soc Nephrol. 2002;13(5):1409–1411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11961031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei C, El hindi S, Li J, et al.Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17(8):952–960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4089394</ArticleId>
            <ArticleId IdType="pubmed">21804539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reiser J, Nast CC, Alachkar N. Permeability factors in focal and segmental glomerulosclerosis. Adv Chronic Kidney Dis. 2014;21(5):417–421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4149759</ArticleId>
            <ArticleId IdType="pubmed">25168830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Artero ML, Sharma R, Savin VJ, Vincenti F. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis. 1994;23(4):574–581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8154495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gohh RY, Yango AF, Morrissey PE, et al.Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant. 2005;5(12):2907–2912.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16303004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larsen CP, Beggs ML, Saeed M, Walker PD. Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy. J Am Soc Nephrol. 2013;24(5):722–725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3636799</ArticleId>
            <ArticleId IdType="pubmed">23520206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markowitz GS, Nasr SH, Stokes MB, D’Agati VD. Treatment with IFN is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010;5(4):607–615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2849683</ArticleId>
            <ArticleId IdType="pubmed">20203164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rönnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol. 2011;23(2):113–121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21292501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010;21(12):2028–2035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21051743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu WX, Chen YH, Bao H, et al.Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study. Lupus. 2015;24(10):1067–1075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25819933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2(2):139–274.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Yu F, Song D, Wang SX, Zhao MH. Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: a large cohort study from a single centre. Rheumatology (Oxford). 2014;53(7):1235–1244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24599917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rovin BH, Caster DJ, Cattran DC, et al.Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2019;95(2):281–295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30665569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shea-simonds P, Cairns TD, Roufosse C, Cook T, Vyse TJ. Lupus podocytopathy. Rheumatology (Oxford). 2009;48(12):1616–1618.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19713441</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
